Erratum: Advertising in medical journals: Should current practices change? (PLOS Medicine (2006) 3, 6 DOI: 10.1371/journal.pmed.0030130);Advertising in medical journals: Should current practices change?

PLoS Medicine

Volumn 3, Issue 6, 2006, Pages 0762-0768

  Fugh Berman, Adriane ^a   Alladin, Karen ^a   Chow, Jarva ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL; TADALAFIL; VARDENAFIL; DRUG;

COST BENEFIT ANALYSIS; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; ERECTILE DYSFUNCTION; HEALTH CARE POLICY; HUMAN; INFORMATION DISSEMINATION; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL PRACTICE; MEDICAL SOCIETY; PHYSICIAN; PRESCRIPTION; PUBLICATION; REVIEW; ADVERTIZING; ARTICLE; ETHICS; FINANCIAL MANAGEMENT; PEER REVIEW; PUBLISHING;

ADVERTISING AS TOPIC; DRUG INDUSTRY; EDITORIAL POLICIES; MARKETING OF HEALTH SERVICES; PEER REVIEW, RESEARCH; PERIODICALS AS TOPIC; PHARMACEUTICAL PREPARATIONS;

EID: 33745599083     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030130     Document Type: Erratum

References (39)

1. O'Connell V (2001 May 22) Medical journals chase drug-ad dollars. Wall Street Journal (Eastern edition); Sect B: 8.
2. [Anonymous] (2000) The value of medical journal advertising. RxPromoROI: A resource for pharmaceutical promotion ROI results. Westfield (New Jersey): Association of Medical Publishers. Available: http://www.amponline.org/Media/ Medical_Journal_Ad_Overview.pdf. Accessed 21 March 2006.
3. [Anonymous] (2003 May) Does size matter for journal ads? Med Mark Media: 28.
4. IMS Health, Integrated Promotional Services, CMR (2004) Top-line industry data. Fairfield (Connecticut): IMS Health. Available: http://www.imshealth.com/ ims/portal/front/articleC/0,2777,6599_44304752_44889690,00.html. Accessed 12 November 2005.
5. Liebman M (2000 March) Listen up, publishers say - Journal advertising sells! Med Mark Media: 89-94.
6. Wang TJ, Ausiello JC, Stafford RS (1999) Trends in antihypertensive drug advertising, 1985-1996. Circulation 99: 2055-2057.
7. Liebman M (1998 June) Finally, predictable returns on promotional investments. Med Mark Media: 64-74.
8. Pizor TC (1998 November) A medical publisher reminds us: Don't forget the gatekeepers. Med Mark Media: 65-67.
9. PERQ/HCI Research (2006) Advertising revenue by medical specialty. Princeton (New Jersey): PERQ/HCI Research. Available: http://www.perqhci.com/ News/spending/ad_revenue_by_class_pfv.html. Accessed 10 March 2006.
10. May EM (2005 April) Journals gather momentum. Med Mark Media: 45-50.
11. [Anonymous] (2005) Advertising rate card. Med Mark Media. Available: http://www.mmm-online.com/content/fileadmin/files/mediainfo/onesheet.pdf. Accessed 20 March 2006.
12. [Anonymous] (2005) New England Journal of Medicine advertising rates and information. Waltham (Massachusetts): New England Journal of Medicine. Available: http://nejmadsales.org/media/pdfs06/06USRateCard.pdf. Accessed 10 March 2006.
13. [Anonymous] (2005) JAMA 2006 rate card, number 60. Chicago: American Medical Association. Available: http://pubs.ama-assn.org/misc/jamarates.pdf. Accessed 10 March 2006.
14. [Anonymous] (2005) Annals of Internal Medicine advertising rate card. Philadelphia (Pennsylvania): American College of Physicians. Available: http://www.acponline.org/journals/advert/annals_rates06.pdf. Accessed 10 March 2006.
15. [Anonymous] (2005) 2006 ACP Internal medicine marketing report: Anatomy of an internist. Philadelphia (Pennsylvania): American College of Physicians. Available: http://www.acponline.org/journals/advert/pharm/start_acp.pdf. Accessed 10 March 2006.
16. [Anonymous] (2005) American Family Physician 2006 rate card. Leawood (Kansas): American Family Physician. Available: http://www.aafp.org/PreBuilt/ afp_ratecard_2006.pdf. Accessed 10 March 2006.
17. Dubois RW (2003) Pharmaceutical promotion: Don't throw the baby out with the bathwater. Health Aff W3-96-W3-103.
18. Ma J, Stafford RS, Cockburn IM, Finkelstein SN (2003) A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clin Ther 25: 1503-1517.
19. Orentlicher D, Hehir MK II (1999) Advertising policies of medical journals: Conflict of interest for journal editors and professional societies. J Law Med Ethics 27: 113-121.
20. American College of Physicians v. US . 3 Cl.Ct 531 (1983).
21. American College of Physicians v. US . 743 F.2d 1570 (1984).
22. US v. American College of Physicians . 475 US 834 (1986).
23. Wilkes MS, Doblin BH, Shapiro MF (1992) Pharmaceutical advertisements in leading medical journals: Experts' assessments. Ann Intern Med 116: 912-919.
24. Cooper RJ, Schriger DL (2005) The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. CMAJ 172: 487-491.
25. Mindell J, Kemp T (1997) Evidence based advertising? Only two fifths of advertisements cited published, peer reviewed references. BMJ 315: 1622.
26. Hafeez A, Mirza Z (1999) Responses from pharmaceutical companies to doctors' requests for more drug information in Pakistan: Postal survey. BMJ 319: 547.
27. McDonnel PJ (2000) Let the buyer (and reader) beware: Targeted advertising in medical journals. Arch Fam Med 9: 125.
28. James A (2002) Medicines, society, and industry. Lancet 360: 1346.
29. [Anonymous] (2005) BMJ rate card 2005. BMJ. Available: http://www.bmjpg.com/advertising. Accessed 20 March 2006.
30. [Anonymous] (2005) The Lancet rate card. London: The Lancet. Available: http://www.elsmediakits.com/ratecards/Lancet.pdf. Accessed 10 March 2006.
31. Glassman PA, Hunter-Hayes J, Nakamura T (1999) Pharmaceutical advertising revenue and physician organizations: How much is too much? West J Med 1: 234-238.
32. American Medical Association [AMA] (2005) 2004 Annual report. Chicago: AMA. Available: http://www.ama-assn.org/ama/pub/category/12528.html. Accessed 10 March 2006.
33. Wilkes MS, Kravitz RL (1995) Policies, practices, and attitudes of North American medical journal editors. J Gen Intern Med 10: 443-450.
34. Altman LK (1999 August 24) Inside medical journals, a rising quest for profits. The New York Times; Sect D: 7.
35. Tsai AC (2003) Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals. Int J Health Serv 33: 751-768.
36. Dyer O (2004) Journal rejects article after objections from the marketing department. BMJ 328: 204.
37. Dyer O (2004) Journal reverses decision on publishing editorial previously rejected by marketing department. BMJ 328: 310.
38. Jureidini J, Mansfield P (2003) The journal and drug advertising. Aust N Z J Psychiatry 37: 495.
39. Kamerow D, Godlee F (2005) BMJ USA is ending. BMJ 331: e394. DOI: 10.1136/bmj.331.7530.E394.